Loading…
Employees: 2,257
Size JIANMIN PHARMACEUTICAL (600976.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $638M, the 3268th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥27.94 on 6 Nov 2026.
Performance Over six months the shares fell 11.8%, against -20.8% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 1.7% over the last twelve months (peer median +6.1%); the operating margin is 8.1% (peer median 4.4%).
Valuation It trades at 7.1× forward earnings against a peer median of 17.7× (cheapest of 8).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.7 points above its cost of capital (6.8% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.12B | CN¥3.35B | CN¥3.48B | CN¥4.18B | CN¥3.62B |
| Revenue growth | — | -4% | -17% | +16% | — |
| Gross profit | CN¥1.86B | CN¥1.91B | CN¥1.61B | CN¥1.88B | CN¥1.52B |
| EBITDA | n/a | CN¥302M | CN¥181M | CN¥372M | CN¥300M |
| Net income | CN¥312M | CN¥360M | CN¥362M | CN¥521M | CN¥408M |
| Free cash flow | CN¥418M | CN¥174M | CN¥311M | CN¥307M | CN¥323M |
| Capital expenditure | CN¥104M | CN¥101M | CN¥120M | CN¥64.5M | CN¥68.0M |
| Total debt | CN¥245M | CN¥292M | CN¥397M | CN¥501M | CN¥367M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600976.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.6% | -5.5% | 6th highest of 21 |
| 6-month return | -11.8% | -20.8% | 9th highest of 21 |
| Distance from 52-week high | -30.7% | -35.8% | 8th highest of 21 |
| Revenue growth (TTM) | -1.7% | +6.1% | 7th lowest of 18 |
| Operating margin | 8.1% | 4.4% | 6th highest of 18 |
| Forward P/E | 7.1× | 17.7× | cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | -4.9% | 6.6% | 2nd least demanding of 11 |
| Growth delivered (Del g) | +6.5% | +4.6% | 5th highest of 11 |
| Hurdle (Req g minus delivered) | -11.4 pp | +2.0 pp | 2nd least demanding of 11 |
| ROIC minus cost of capital | +7.7 pp | -4.0 pp | 2nd highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 7.1× | -4.9% | +6.5% |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | n/a | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | n/a | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | n/a | 12.1% | -5.9% |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 30.1× | 23.2% | +21.9% |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 30.4× | 25.4% | +31.4% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | n/a | 1.1% | -1.6% |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 10.9× | -14.3% | +2.8% |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 61.2× | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | n/a | 0.3% | -17.9% |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | n/a | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | n/a | n/a | n/a |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 12.6× | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | n/a | 25.9% | +10.3% |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | n/a | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | n/a | 50.8% | +16.2% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 12.7× | -2.4% | +6.4% |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 17.7× | -2.5% | -1.8% |